Genes involved in the induction and resolution of eczema using the Atopy Patch Test as an in vivo model for atopic dermatitis

Completed

• Conditions: atopic dermatitis (AD); 10014982; atopic eczema (AE)

• Registration Number: NL-OMON44326
• Lead Sponsor: niversitair Medisch Centrum Utrecht

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 10

Inclusion Criteria

age 18-70 years
AE
positive APT

Exclusion Criteria

Active AE on the patients back
- Not sensitized to aeroallergens, such as house dust mite (demonstrated by a positive immuno CAP test for these allergens)
- Treatment with systemic immunosuppressive medication (including corticosteroids and cyclosporin) within the 4 weeks prior to having the biopsies performed. In addition, weekly use of equal or more than 50 grams of topical corticosteroids class IV or weekly use of equal or more than 100 grams of topical corticosteroids class III.
- Exposure of biopsy location to high levels of UV radiation (e.g. UV-therapy, use of tanning booths, sunbathing) in the 2 weeks prior to taking biopsies
- Use of antihistamines in the week or days before and during the APT ( see patientinformation 'Bijlage 4: medicatielijst')

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Ex vivo: mRNA expression levels of the measured markers with qPCR in snap<br /><br>frozen tissue.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Ex vivo: localization of the markers with IHC on frozen slides.</p><br>